We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Sekisui Diagnostics UK Ltd.

Download Mobile App




R&D Partnership Initiated to Reduce Development Time for New Drugs

By LabMedica International staff writers
Posted on 09 Dec 2014
Print article
nanoPET Pharma, GmbH (Berlin, Germany) signed an open-ended framework contract with the international pharmaceutical company Boehringer Ingelheim (Ridgefield, CT, USA). By developing customized contrast agents for research in both basic and preclinical studies, nanoPET Pharma will contribute to the enhancement of Boehringer Ingelheim’s imaging diagnostics. The first joint projects have already begun and many more are being planned.


After several years of close collaboration between Boehringer Ingelheim and nanoPET Pharma, there now exists a framework contract between the two companies. This contract has a long-term perspective and will include various joint projects. “This cooperation model is based on a true partnership,” explained Dr. Andreas Briel, CEO of nanoPET Pharma. “Research, development, and marketing of therapeutic substances will be led by Boehringer Ingelheim; preclinical diagnostics will be managed by nanoPET. This ensures that the business fields remain strictly separate and that both partners benefit.”

The aim of the projects is to support Boehringer Ingelheim in the early identification of suitable drug candidates, to accelerate the process and, at the same time, to lessen the preclinical phase through the use of optimized imaging technology. Customized contrast agents enable the implementation of high-resolution in vivo monitoring techniques with resolutions down to the micrometer range in preclinical studies. Of importance to note is that such methods also enable a reduction in the number of laboratory animals. Of course, during the past several years, regulatory authorities constantly demand proof of the use of sophisticated imaging modalities in drug development, during the preparation of approval documentation.

Dr. Andreas Briel concluded, “We provide what any pharmaceutical development company needs during the preclinical phase: a clear and significant image which protects the living organism. Our services support the 3R-concept of “replace, reduce, and refine.”

Within this collaboration, nanoPET Pharma scientists will also study, in the medium-term, opportunities for the implementation of imaging methods as companion diagnostics in human medicine.

nanoPET Pharma explores and develops various diagnostic imaging agents. A section of the company’s core business is the proprietary product line with 21 substances, which are applied in magnetic resonance imaging (MRI), computed tomography (CT), optical imaging, and ultrasound in preclinical research worldwide. Furthermore, nanoPET Pharma develops specialized contrast agents for implementation in pharmaceutical research. Moreover, nanoPET focusses on positron-emitting inorganic nanoparticles for molecular and cell-specific positron emission tomography (PET) imaging, a diagnostic tool that allows imaging of the human body. The market potential of this technology is estimated at several hundred million Euros.

Related Links:
nanoPET Pharma
Boehringer Ingelheim


Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Unit-Dose Packaging solution
HLX
New
ELISA System
ABSOL HS DUO
New
Cortisol Rapid Test
Finecare Cortisol Rapid Quantitative Test

Print article

Channels

Clinical Chemistry

view channel
Image: The new saliva-based test for heart failure measures two biomarkers in about 15 minutes (Photo courtesy of Trey Pittman)

POC Saliva Testing Device Predicts Heart Failure in 15 Minutes

Heart failure is a serious condition where the heart muscle is unable to pump sufficient oxygen-rich blood throughout the body. It ranks as a major cause of death globally and is particularly fatal for... Read more

Molecular Diagnostics

view channel
Image: Schematic overview of maternal biomarker discovery using cell-free RNA during pregnancy (Photo courtesy of Circulation Research (2024). DOI: 10.1161/CIRCRESAHA.124.325024)

Maternal Blood Test Identifies Congenital Heart Diseases in Fetus

Each year, around 1,000 children are born with a single ventricle heart defect (SVHD), a condition where one of the heart's lower chambers is underdeveloped, too small, or missing a valve.... Read more

Hematology

view channel
Image: QScout CBC will give a complete blood count in 2 minutes from fingerstick or venous blood (Photo courtesy of Ad Astra Diagnostics)

Next Gen CBC and Sepsis Diagnostic System Targets Faster, Earlier, Easier Results

Every hour is critical in protecting patients from infections, yet there are currently limited tools to assist in early diagnosis before patients reach a hospital. The complete blood count (CBC) is a common... Read more

Microbiology

view channel
Image: The InfectoSynovia test has the potential to revolutionize the diagnosis of periprosthetic joint infection (Photo courtesy of 123RF)

High-Accuracy Bedside Test to Diagnose Periprosthetic Joint Infection in Five Minutes

Periprosthetic joint infection (PJI) represents a significant global issue that is worsening as the number of joint replacements increases due to aging populations. In the United States alone, the anticipated... Read more

Pathology

view channel
Image

AI-Based Method Shows Promise for Pathological Diagnosis of Hereditary Kidney Diseases

Alport syndrome is a hereditary kidney disorder characterized by kidney dysfunction, sensorineural hearing loss, and ocular abnormalities. Early in the disease, patients experience hematuria, which is... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.